Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators.

Ann Oncol. 2019 May;30(5):766-773. doi: 10.1093/annonc/mdz061. Epub 2019 Dec 4.

PMID:
31987343
2.

Cyclin G2 regulates canonical Wnt signalling via interaction with Dapper1 to attenuate tubulointerstitial fibrosis in diabetic nephropathy.

Zhao C, Gao J, Li S, Liu Q, Hou X, Xing X, Wang D, Sun M, Wang S, Luo Y.

J Cell Mol Med. 2020 Jan 24. doi: 10.1111/jcmm.14946. [Epub ahead of print]

3.

Mesenchymal stem cells ameliorate β cell dysfunction of human type 2 diabetic islets by reversing β cell dedifferentiation.

Wang L, Liu T, Liang R, Wang G, Liu Y, Zou J, Liu N, Zhang B, Liu Y, Ding X, Cai X, Wang Z, Xu X, Ricordi C, Wang S, Shen Z.

EBioMedicine. 2020 Jan 6;51:102615. doi: 10.1016/j.ebiom.2019.102615. [Epub ahead of print]

4.

Hypoxia-inducible factor-1α mediates the expression of mature β cell-disallowed genes in hypoxia-induced β cell dedifferentiation.

Liu N, Cai X, Liu T, Zou J, Wang L, Wang G, Liu Y, Ding X, Zhang B, Sun P, Liang R, Wang S.

Biochem Biophys Res Commun. 2019 Dec 19. pii: S0006-291X(19)32393-9. doi: 10.1016/j.bbrc.2019.12.063. [Epub ahead of print]

PMID:
31866014
5.

Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.

Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, Liu J, Wang S, Hu X, Zheng W, Chen Z, Yang Q, Jiang Z.

Ann Transl Med. 2019 Sep;7(18):482. doi: 10.21037/atm.2019.07.95.

6.

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.

Shao Z, Pang D, Yang H, Li W, Wang S, Cui S, Liao N, Wang Y, Wang C, Chang YC, Wang H, Kang SY, Seo JH, Shen K, Laohawiriyakamol S, Jiang Z, Li J, Zhou J, Althaus B, Mao Y, Eng-Wong J.

JAMA Oncol. 2019 Oct 24. doi: 10.1001/jamaoncol.2019.3692. [Epub ahead of print]

PMID:
31647503
7.

Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer.

Zhai Q, Fan J, Lin Q, Liu X, Li J, Hong R, Wang S.

PLoS One. 2019 Oct 4;14(10):e0223325. doi: 10.1371/journal.pone.0223325. eCollection 2019.

8.

Berberine protects steatotic donor undergoing liver transplantation via inhibiting endoplasmic reticulum stress-mediated reticulophagy.

Zhang N, Sheng M, Wu M, Zhang X, Ding Y, Lin Y, Yu W, Wang S, Du H.

Exp Biol Med (Maywood). 2019 Dec;244(18):1695-1704. doi: 10.1177/1535370219878651. Epub 2019 Sep 25. No abstract available.

PMID:
31554427
9.

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.

Lu Q, Xia W, Lee K, Zhang J, Yuan H, Yuan Z, Shi Y, Wang S, Xu F.

Oncologist. 2020 Jan;25(1):21-e15. doi: 10.1634/theoncologist.2019-0564. Epub 2019 Aug 21.

10.

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.

Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, Li H, Yu S, Feng J, Wang S, Hu X, Zou J, Zhu X, Xu B.

J Clin Oncol. 2019 Oct 10;37(29):2610-2619. doi: 10.1200/JCO.19.00108. Epub 2019 Aug 20.

PMID:
31430226
11.

Opposing effects of IL-1β/COX-2/PGE2 pathway loop on islets in type 2 diabetes mellitus.

Wang G, Liang R, Liu T, Wang L, Zou J, Liu N, Liu Y, Cai X, Liu Y, Ding X, Zhang B, Wang Z, Wang S, Shen Z.

Endocr J. 2019 Aug 29;66(8):691-699. doi: 10.1507/endocrj.EJ19-0015. Epub 2019 May 18.

12.

The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.

Su Y, Huang J, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y, Li J, Gao Y, Shi W, Wang X, Peng R, Xu F, An X, Xue C, Xia W, Hong R, Zhong Y, Lin Y, Huang H, Zhang A, Zhang L, Cai L, Zhang J, Yuan Z.

J Natl Cancer Inst. 2020 Jan 1;112(1):55-62. doi: 10.1093/jnci/djz086.

PMID:
31093677
13.

Proliferation of human hepatocellular carcinoma cells from surgically resected specimens under conditionally reprogrammed culture.

Wang Z, Bi B, Song H, Liu L, Zheng H, Wang S, Shen Z.

Mol Med Rep. 2019 Jun;19(6):4623-4630. doi: 10.3892/mmr.2019.10160. Epub 2019 Apr 12.

14.

Corrigendum to "Cyclin G2 Suppresses Glomerulosclerosis by Regulating Canonical Wnt Signalling".

Zhao C, Gao J, Li S, Liu Q, Hou X, Liu S, Xing X, Sun M, Wang S, Luo Y.

Biomed Res Int. 2019 Apr 1;2019:4104265. doi: 10.1155/2019/4104265. eCollection 2019.

15.

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X.

Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27.

PMID:
31036468
16.

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Wang J, Li W, Shi Y, Huang Y, Sun T, Tang L, Lu Q, Lei Q, Liao N, Jin F, Li H, Huang T, Qian J, Pang D, Wang S, Fan P, Wu X, Lin Y, Qin H, Xu B.

Cancer Med. 2019 May;8(5):2074-2084. doi: 10.1002/cam4.2093. Epub 2019 Apr 13.

17.

Panobinostat (LBH589) inhibits Wnt/β-catenin signaling pathway via upregulating APCL expression in breast cancer.

Qin G, Li Y, Xu X, Wang X, Zhang K, Tang Y, Qiu H, Shi D, Zhang C, Long Q, Lee K, Zhai Q, Wang S, Chen M, Deng W.

Cell Signal. 2019 Jul;59:62-75. doi: 10.1016/j.cellsig.2019.03.014. Epub 2019 Mar 14.

PMID:
30880222
18.

Preventing BRCA1/ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation.

Hong R, Zhang W, Xia X, Zhang K, Wang Y, Wu M, Fan J, Li J, Xia W, Xu F, Chen J, Wang S, Zhan Q.

Mol Oncol. 2019 Apr;13(4):959-977. doi: 10.1002/1878-0261.12466. Epub 2019 Mar 1.

19.

CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.

Zhang K, Hong R, Kaping L, Xu F, Xia W, Qin G, Zheng Q, Lu Q, Zhai Q, Shi Y, Yuan Z, Deng W, Chen M, Wang S.

Cancer Lett. 2019 Apr 10;447:130-140. doi: 10.1016/j.canlet.2019.01.005. Epub 2019 Jan 21.

PMID:
30677445
20.

Cyclin G2 Suppresses Glomerulosclerosis by Regulating Canonical Wnt Signalling.

Zhao C, Gao J, Li S, Liu Q, Hou X, Liu S, Xing X, Sun M, Wang S, Luo Y.

Biomed Res Int. 2018 Oct 21;2018:6938482. doi: 10.1155/2018/6938482. eCollection 2018. Erratum in: Biomed Res Int. 2019 Apr 1;2019:4104265.

Supplemental Content

Loading ...
Support Center